-
Digital advisory & IT consulting
Mastering digitalisation together
-
Operational Advisory
Solidifying and supporting transformation
-
Deal Advisory
We’ll advise you on national and international transactions
-
Valuation & economic and dispute advisory
We’ll value your business fairly and realistically
-
Debt advisory & treasury services
Funding and treasury consulting to the client’s advantage
-
Tax for businesses
Because your business – national or international – deserves better tax advice.
-
Tax for financial institutions
Financial services tax – for banks, asset managers and insurance companies
-
Global mobility services
Avoid double taxation – and minimise costs
-
Employment law
Representation for businesses
-
Commercial & distribution
Making purchasing and distribution legally water-tight.
-
Inheritance and succession
Don’t leave the future to chance.
-
Financial Services | Legal
Your Growth, Our Commitment.
-
Business legal
Doing business successfully by optimally structuring companies
-
Real estate law
We cover everything on the real estate sector, the hotel industry, and the law governing construction and architects, condominium ownership, and letting and renting.
-
IT, IP and data protection
IT security and digital innovations
-
Mergers & acquisitions (M&A)
Your one-stop service provider focusing on M&A transactions
-
International business
Our country expertise
-
Entering the German market
Your reliable partners.
Düsseldorf, 15 August 2024
Grünenthal GmbH (“Grünenthal”), a globally leading privately-owned pharmaceutical company in the area of pain management, recently announced its acquisition of the US company Valinor Pharma LLC (“Valinor”) and its product Movantik® (Naloxegol). The total value of the transaction is around 250 million US dollars, including all royalty obligations.
An interdisciplinary, cross-border team from Grant Thornton Germany and Grant Thornton US successfully assisted Grünenthal with the transaction in financial due diligence and the sales agreement negotiations.
Grünenthal is a global leader in pain management and related diseases. The company is headquartered in Aachen, Germany, and has affiliates in 27 countries across Europe, Latin America, and the USA. Grünenthal products are available in approx. 100 countries. In 2023, the company employed around 4,400 people and achieved revenues of €1.8 billion.
Movantik® is indicated for the oral treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The transaction further expands Grünenthal’s portfolio of established medicines and adds to the company’s growing U.S. business. Gross sales from Movantik® in the United States reached over $200 million in 2023.
Team
Financial advisory
Tobias Kluth
Partner (Düsseldorf)
+49 211 9524 8106
tobias.kluth@de.gt.com
Sven Kirse
Senior Manager (Düsseldorf)
+49 211 9524 8391
sven.kirse@de.gt.com
Maxwell G. Mitchell
Managing Director (Grant Thornton US)
+1 312 602 8387
max.mitchell@us.gt.com
Glenn Barenbaum
Principal (Grant Thornton US)
+1 215 814 1730
glenn.barenbaum@us.gt.com
Kurt Reitzel
Senior Manager (Grant Thornton US)
kurt.reitzel@us.gt.com
Tyler Wegter
Senior Associate (Grant Thornton US)
tyler.wegter@us.gt.com
About Grant Thornton in Germany
Grant Thornton AG is one of the ten largest audit firms in Germany, providing services to upper mid-market companies and listed companies, with around 1,900 employees at ten offices. The audit and advisory firm consists of the service lines Audit & Assurance, Tax, Advisory and Legal. The firm is legally independent. To be able to serve national clients internationally as well, the firm is a member of the international Grant Thornton International Ltd network (GTIL). GTIL and its member firms are not a worldwide partnership but legally independent entities. With around 73,000 employees, the Grant Thornton network advises companies in around 149 countries across the world. www.grantthornton.de
Kontakt
Willi Keipper
Manager PR & Corporate Communications
+49 30 8904 82106
willi.keipper@de.gt.com